Profile data is unavailable for this security.
About the company
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
- Revenue in USD (TTM)0.00
- Net income in USD-117.37m
- Incorporated2019
- Employees6.00
- LocationLENZ Therapeutics Inc445 Marine View Ave Suite 320DEL MAR 92014United StatesUSA
- Phone+1 (858) 925-7000
- Fax+1 (302) 658-3989
- Websitehttps://graphitebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cibus Inc | 2.32m | -285.67m | 356.99m | 183.00 | -- | 1.09 | -- | 153.87 | -18.29 | -18.29 | 0.1522 | 13.24 | 0.0084 | -- | -- | 12,677.60 | -129.84 | -86.28 | -147.90 | -96.45 | -- | -- | -15,483.49 | -792.07 | -- | -3.17 | 0.0039 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
| Verrica Pharmaceuticals Inc | 8.91m | -80.74m | 360.99m | 100.00 | -- | 239.39 | -- | 40.50 | -1.75 | -1.75 | 0.1929 | 0.0356 | 0.1321 | -- | 2.33 | 89,130.00 | -119.66 | -55.75 | -142.98 | -78.33 | 79.63 | -- | -905.83 | -754.94 | 3.04 | -21.71 | 0.9678 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Aura Biosciences Inc | 0.00 | -78.65m | 364.14m | 88.00 | -- | 1.74 | -- | -- | -1.86 | -1.86 | 0.00 | 4.22 | 0.00 | -- | -- | 0.00 | -35.66 | -- | -37.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Organogenesis Holdings Inc | 435.47m | 5.82m | 364.57m | 862.00 | 63.25 | 1.31 | 17.17 | 0.8372 | 0.0435 | 0.0435 | 3.28 | 2.11 | 0.9628 | 4.08 | 4.63 | 505,190.30 | 1.29 | 5.46 | 1.56 | 6.90 | 75.07 | 74.94 | 1.34 | 4.81 | 2.41 | 8.78 | 0.1955 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Biomea Fusion Inc | 0.00 | -127.27m | 378.14m | 110.00 | -- | 2.79 | -- | -- | -3.57 | -3.57 | 0.00 | 3.77 | 0.00 | -- | -- | 0.00 | -90.54 | -- | -107.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Anika Therapeutics Inc | 169.26m | -76.83m | 380.35m | 357.00 | -- | 1.82 | -- | 2.25 | -5.24 | -5.24 | 11.54 | 14.07 | 0.5616 | 1.42 | 5.40 | 474,120.40 | -25.49 | -5.41 | -28.16 | -5.87 | 61.96 | 60.70 | -45.39 | -12.60 | 3.85 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| enGene Holdings Inc | 0.00 | -106.80m | 387.65m | 33.00 | -- | 3.27 | -- | -- | -4.60 | -4.60 | 0.00 | 2.69 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.37 | 0.2653 | -- | -- | -- | -260.87 | -- | -- | -- |
| Terns Pharmaceuticals Inc | 0.00 | -91.06m | 388.71m | 66.00 | -- | 1.64 | -- | -- | -1.26 | -1.26 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -33.23 | -41.34 | -34.55 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| Lenz Therapeutics Inc | 0.00 | -117.37m | 390.42m | 6.00 | -- | 1.97 | -- | -- | -15.88 | -15.88 | 0.00 | 7.77 | 0.00 | -- | -- | 0.00 | -44.51 | -- | -47.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
| Jasper Therapeutics Inc | 0.00 | -63.93m | 391.62m | 45.00 | -- | 3.46 | -- | -- | -5.60 | -5.60 | 0.00 | 7.51 | 0.00 | -- | -- | 0.00 | -48.30 | -- | -51.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Contineum Therapeutics Inc | 50.00m | 19.13m | 394.08m | 31.00 | 20.13 | -- | 20.36 | 7.88 | 0.7611 | 0.7611 | 1.99 | 4.66 | -- | -- | -- | 1,612,903.00 | -- | -- | -- | -- | -- | -- | 38.25 | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -22.53m | 398.52m | 10.00 | -- | -- | -- | -- | -1.03 | -1.03 | 0.00 | -0.1181 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
| ACELYRIN Inc | 0.00 | -240.16m | 407.99m | 130.00 | -- | 0.6324 | -- | -- | -2.59 | -2.59 | 0.00 | 6.52 | 0.00 | -- | -- | 0.00 | -48.23 | -- | -52.78 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Esperion Therapeutics Inc | 229.74m | -86.51m | 409.23m | 240.00 | -- | -- | -- | 1.78 | -1.00 | -1.00 | 1.76 | -1.57 | 0.7353 | 0.7415 | 5.05 | 957,250.00 | -27.69 | -69.45 | -47.42 | -101.81 | 81.85 | -- | -37.65 | -147.44 | 1.78 | -0.6581 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Fate Therapeutics Inc | 6.48m | -190.05m | 418.90m | 181.00 | -- | 0.9828 | -- | 64.67 | -1.92 | -1.92 | 0.0653 | 3.74 | 0.0108 | -- | 0.9024 | 35,790.05 | -31.67 | -31.82 | -34.36 | -36.05 | -- | -- | -2,933.79 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Theravance Biopharma Inc | 61.51m | -44.77m | 419.22m | 99.00 | -- | 2.04 | -- | 6.82 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
Data as of May 31 2024. Currency figures normalised to LENZ Therapeutics Inc's reporting currency: US Dollar USD
54.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Mar 2024 | 4.18m | 16.37% |
| Alpha Wave Global LPas of 31 Mar 2024 | 3.61m | 14.15% |
| Point72 Asset Management LPas of 31 Mar 2024 | 1.88m | 7.37% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 1.22m | 4.78% |
| Sectoral Asset Management, Inc.as of 31 Mar 2024 | 1.07m | 4.19% |
| RTW Investments LPas of 31 Mar 2024 | 863.39k | 3.38% |
| Tang Capital Management LLCas of 31 Mar 2024 | 547.62k | 2.15% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 218.75k | 0.86% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 202.50k | 0.79% |
| Alyeska Investment Group LPas of 31 Mar 2024 | 199.60k | 0.78% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
